Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of bone-modifying agents and inhibits angiogenesis agents. Although the pathogenesis of MRONJ is not entirely clear, multiple factors may be involved in specific microenvironments. The TGF-β1 signalling pathway may have a key role in the development of MRONJ. According to the clinical stage, multiple variables should be considered when selecting the most appropriate treatment. Therefore, the prevention and management of treatment of MRONJ should be conducted in patient-centred multidisciplinary team collaborative networks with oncologists, dentists and dental specialists. This would comprise a closed responsibility treatment loop with all benefits directed to the patient. Thus, in the present review, we aimed to summarise the pathogenesis, risk factors, imaging features, clinical staging, therapeutic methods, prevention and treatment strategies associated with MRONJ, which may provide a reference that can inform preventive strategies and improve the quality of life for patients in the future.

药物相关的颌骨坏死（MRONJ）是骨修饰剂的严重副作用，并抑制血管生成剂。尽管MRONJ的发病机制尚不完全清楚，但特定的微环境可能涉及多种因素。TGF-β1信号通路可能在MRONJ的发展中起关键作用。根据临床阶段，选择最合适的治疗方法应考虑多个变量。因此，应在以患者为中心的多学科团队合作网络中与肿瘤科医生，牙医和牙科专家进行预防和管理MRONJ。这将包括一个封闭的责任治疗循环，所有收益都直接分配给患者。因此，在本综述中，我们旨在总结发病机理，危险因素，影像学特征，